Montag A & Associates Inc. Sells 8,571 Shares of Abbott Laboratories $ABT

Montag A & Associates Inc. reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,857 shares of the healthcare product maker’s stock after selling 8,571 shares during the quarter. Montag A & Associates Inc.’s holdings in Abbott Laboratories were worth $12,511,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories in the third quarter valued at $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories in the third quarter valued at $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 1.4%

ABT opened at $89.51 on Friday. Abbott Laboratories has a fifty-two week low of $89.14 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.18 and a current ratio of 1.39. The company has a market capitalization of $155.90 billion, a P/E ratio of 25.07, a P/E/G ratio of 1.49 and a beta of 0.66. The stock has a fifty day moving average of $104.33 and a 200-day moving average of $116.09.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm earned $1.09 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 22,200 shares of company stock valued at $2,215,100 and have sold 3,055 shares valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Citigroup cut their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Argus cut their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Jefferies Financial Group cut their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Piper Sandler cut their price target on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.